Biosimilars 2020 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 4, 2021
For the first time since FDA licensed the first biosimilar, Sandoz’s Zarxio ® (filgrastim-sndz), in 2015, the United States saw a decrease in annual biosimilar approvals in 2020. Figure 1, below, provides a snapshot of FDA approval and biosimilar product launch trends from 2015 through 2020. 2015; resubmitted Feb. Conclusion.
52 
Let's personalize your content